Onoue, T., Goto, M., Wada, E., Furukawa, M., Okuji, T., Okada, N., . . . Arima, H. (2020). Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial. PLoS One.
Styl cytowania ChicagoOnoue, Takeshi, et al. "Dipeptidyl Peptidase-4 Inhibitor Anagliptin Reduces Fasting Apolipoprotein B-48 Levels in Patients With Type 2 Diabetes: A Randomized Controlled Trial." PLoS One 2020.
Styl cytowania MLAOnoue, Takeshi, et al. "Dipeptidyl Peptidase-4 Inhibitor Anagliptin Reduces Fasting Apolipoprotein B-48 Levels in Patients With Type 2 Diabetes: A Randomized Controlled Trial." PLoS One 2020.
Uwaga: Te cytaty mogą odróżniać się od wytycznej twojego fakultetu..